FDA 483 at Houston RX: 14 Sterility Findings Behind Recalled Compounded Tirzepatide Vials
A six-day FDA inspection of Houston RX yielded 14 Form 483 observations, including research-grade tirzepatide certificates, before 64 compounded tirzepatide vials were recalled.
Read article →